Regeneron Reports registry Data for Risankizumab in Colorectal cancer

Regeneron today announced registry results for risankizumab in patients with colorectal cancer. The study demonstrated that risankizumab demonstrates safety and tolerability compared to standard of care or placebo. These results provide important insights into the treatment of colorectal cancer and support the continued development of risankizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.